Mirdametinib in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
J. Clin. Oncol 2021 Jan 28;[EPub Ahead of Print], BD Weiss, PL Wolters, SR Plotkin, BC Widemann, JH Tonsgard, J Blakeley, JC Allen, E Schorry, B Korf, NJ Robison, S Goldman, AA Vinks, C Emoto, T Fukuda, CT Robinson, G Cutter, L Edwards, E Dombi, N Ratner, R Packer, MJ FisherFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.